Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Dermata Therapeutics, Inc. DRMA

Healthcare  —  Biotechnology
1.14 (0.03) (2.56%) as of 25 Sep
Market cap
$4.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Dermata Therapeutics, Inc. (DRMA) Business Profile

Updated before January 2025

Company Overview

Dermata Therapeutics, Inc. (NASDAQ: DRMA) is a clinical-stage biotechnology company focused on developing and commercializing innovative pharmaceutical products for the treatment of dermatological and ocular diseases. Founded in 2014 and headquartered in San Diego, California, Dermata leverages its proprietary Spongilla technology platform to create novel therapies that address unmet medical needs in dermatology and ophthalmology. The company is led by an experienced management team, including Dr. Gerry Proehl, Co-Founder, Chairman, and CEO, who brings decades of expertise in pharmaceutical development and commercialization.

Core Business Segments

Dermatology

Dermata’s primary focus is on dermatological conditions, with its lead product candidate, DMT310, targeting multiple skin diseases. DMT310 is a once-weekly topical treatment derived from a natural freshwater sponge, Spongilla lacustris, and is being developed for acne vulgaris, rosacea, and other inflammatory skin conditions. The product’s unique mechanism of action combines mechanical, chemical, and biological properties to exfoliate the skin, reduce inflammation, and deliver therapeutic benefits.

Ophthalmology

In addition to dermatology, Dermata is exploring applications of its Spongilla technology in ophthalmology. The company is developing DMT410, a product candidate designed to treat ocular diseases such as blepharitis and dry eye syndrome. By leveraging its proprietary platform, Dermata aims to address significant unmet needs in the eye care market.

Business Model

Dermata Therapeutics operates as a research-driven biotechnology company with a focus on developing innovative therapies for dermatological and ocular conditions. The company generates revenue primarily through partnerships, licensing agreements, and potential future product sales. Dermata’s business model emphasizes:

  • Proprietary Technology: The Spongilla platform serves as the foundation for its product pipeline, enabling the development of unique therapies with multiple applications.
  • Clinical Development: Dermata invests heavily in clinical trials to demonstrate the safety and efficacy of its product candidates, paving the way for regulatory approval and commercialization.
  • Strategic Collaborations: The company seeks partnerships with pharmaceutical and biotechnology firms to accelerate development and expand market reach.

Strategic Direction

Dermata Therapeutics is committed to advancing its pipeline of innovative therapies and achieving long-term growth. Key strategic priorities include:

  • Pipeline Expansion: The company plans to explore additional indications for its Spongilla-based products, including other dermatological and ocular diseases.
  • Regulatory Approvals: Dermata is focused on completing clinical trials and obtaining FDA approval for its lead product candidates, DMT310 and DMT410.
  • Commercialization: The company aims to establish a strong commercial presence in the dermatology and ophthalmology markets through strategic partnerships and direct sales efforts.
  • Sustainability: Dermata is dedicated to sustainable practices in product development and manufacturing, leveraging natural and renewable resources like Spongilla lacustris.

Competitive Landscape

Dermata Therapeutics operates in a competitive biotechnology landscape, facing competition from established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Dermatology: Companies like Galderma, Allergan (a subsidiary of AbbVie), and Bausch Health offer a range of dermatological treatments, including acne and rosacea therapies.
  • Ophthalmology: Firms such as Alcon, Novartis, and Johnson & Johnson Vision are major players in the eye care market, providing treatments for dry eye, blepharitis, and other ocular conditions.
  • Innovative Platforms: Emerging biotech companies with proprietary technologies, such as Foamix Pharmaceuticals and Verrica Pharmaceuticals, also compete in the dermatology space.

Risk Factors

Dermata Therapeutics faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The approval process for new drugs is lengthy and uncertain, posing a significant risk to the company’s product pipeline.
  • Market Dependence: Dermata’s success depends on the commercial viability of its lead product candidates, DMT310 and DMT410.
  • Supply Chain Disruptions: The company relies on specialized raw materials, such as Spongilla lacustris, which could be affected by environmental or logistical issues.
  • Competition: Intense competition from established pharmaceutical companies and emerging biotech firms may limit Dermata’s market share.
  • Financial Constraints: As a clinical-stage company, Dermata relies on external funding to support its operations and may face challenges in securing additional capital.

Recent Developments

Dermata Therapeutics has made significant progress in advancing its product pipeline and corporate strategy:

  • Clinical Trials: The company recently announced positive results from Phase 2 clinical trials of DMT310 for the treatment of acne vulgaris, demonstrating its safety and efficacy.
  • Regulatory Milestones: Dermata has engaged with the FDA to discuss the regulatory pathway for DMT310 and plans to initiate Phase 3 trials in the near future.
  • Corporate Partnerships: The company is actively seeking strategic collaborations to accelerate the development and commercialization of its product candidates.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of innovative healthcare solutions, creating opportunities for Dermata to address unmet medical needs in dermatology and ophthalmology.

Investment Considerations

Strengths

  • Innovative Technology: Dermata’s proprietary Spongilla platform offers a unique approach to treating dermatological and ocular diseases.
  • Experienced Leadership: The management team has a proven track record in pharmaceutical development and commercialization.
  • Pipeline Potential: The company’s lead product candidates, DMT310 and DMT410, target large and growing markets with significant unmet needs.

Risks

  • Regulatory Uncertainty: The approval process for new drugs is inherently risky and time-consuming.
  • Financial Dependence: Dermata relies on external funding to support its operations and may face challenges in raising additional capital.
  • Market Competition: The company operates in a highly competitive landscape, with established players and emerging biotech firms vying for market share.

Conclusion

Dermata Therapeutics, Inc. is a promising clinical-stage biotechnology company with a focus on developing innovative therapies for dermatological and ocular diseases. Leveraging its proprietary Spongilla technology platform, the company is well-positioned to address significant unmet medical needs in these markets. While Dermata faces challenges such as regulatory uncertainty and intense competition, its experienced leadership team and robust pipeline provide a strong foundation for future growth. As the company advances its product candidates through clinical development and regulatory approval, it has the potential to become a key player in the dermatology and ophthalmology sectors.